Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 8, 2014, Pages 1283-1293

  Peiffer, Lukas ^a   Poll Wolbeck, Simon Jonas ^a   Flamme, Hanna ^a   Gehrke, Iris ^b   Hallek, Michael ^a   Kreuzer, Karl Anton ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

CLL; HDACi; Trichostatin A; WNT signaling

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENDAMUSTINE; CASPASE 3; CASPASE 7; CYCLOPHOSPHAMIDE; DICKKOPF 1 PROTEIN; DNA; FLUDARABINE; MESSENGER RNA; RITUXIMAB; TRICHOSTATIN A; VORINOSTAT; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DEACETYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INDUCTION; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; HISTONE ACETYLATION; HISTONE DEACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCREENING; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; PROTEIN PROCESSING, POST-TRANSLATIONAL; SEQUENCE DELETION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84904299452     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1689-0     Document Type: Article

References (44)

1. Billin AN, Thirlwell H, Ayer DE (2000) Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol 20:6882-6890
2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. doi:10.1038/nrd2133 (Pubitemid 44348499)
3. Cadigan KM (2008) Wnt-beta-catenin signaling. Curr Biol 18:R943-R947. doi:10.1016/j.cub.2008.08.017
4. Cadigan KM, Nusse R (1997) Wnt signaling: a common theme in animal development. Genes Dev 11:3286-3305 (Pubitemid 28023954)
5. De Ruijter AJM, van Gennip AH, Caron HN et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749. doi:10.1042/BJ20021321 (Pubitemid 36399066)
6. Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017-1029. doi:10.1016/S0140-6736(08)60456-0 (Pubitemid 351389535)
7. Döhner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589
8. Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916. doi:10.1056/NEJM200012283432602 (Pubitemid 32064784)
9. Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39. doi:10.1182/blood-2006-06-025999 (Pubitemid 46053039)
10. Eichhorst B, Dreyling M, Robak T, et al (2011) Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:vi50-vi54. doi:10.1093/annonc/mdr377
11. Filipovich A, Gandhirajan RK, Gehrke I et al (2010) Evidence for non-functional Dickkopf-1 (DKK-1) signaling in chronic lymphocytic leukemia (CLL). Eur J Haematol 85:309-313. doi:10.1111/j.1600-0609.2010.01494.x
12. Frye R, Myers M, Axelrod KC et al (2012) Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs 16:195-204. doi:10.1188/12.CJON.195-204
13. Fuino L, Bali P, Wittmann S et al (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971-984
14. Gonzalez D, Martinez P, Wade R et al (2011) Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 29:2223-2229. doi:10.1200/JCO.2010.32.0838
15. Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. doi:10.1002/ajh.23491
16. Isin M, Yenerel M, Aktan M et al (2012) Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia. DNA Cell Biol 31:777-782. doi:10.1089/dna.2011.1314
17. Iwamoto M, Friedman EJ, Sandhu P, et al Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 1-16. doi:10.1007/s00280-013-2220-z
18. Kim MS, Blake M, Baek JH et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300 (Pubitemid 37413470)
19. Lento W, Congdon K, Voermans C et al (2013) Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol. doi:10.1101/ cshperspect.a008011
20. Lin H-Y, Chen C-S, Lin S-P et al (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397-413. doi:10.1002/med.20056 (Pubitemid 43939200)
21. Lu D, Zhao Y, Tawatao R et al (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101:3118-3123. doi:10.1073/pnas.0308648100 (Pubitemid 38327744)
22. Lu D, Liu JX, Endo T et al (2009) Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS ONE 4:e8294. doi:10.1371/journal.pone.0008294
23. Mao B, Wu W, Li Y et al (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321-325. doi:10.1038/35077108 (Pubitemid 32467039)
24. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotech 25:84-90. doi:10.1038/nbt1272 (Pubitemid 46087907)
25. Montserrat E, Bosch F, Rozman C (1997) Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives. J Intern Med Suppl 740:63-67
26. Montserrat E, Moreno C, Esteve J et al (2006) How I treat refractory CLL. Blood 107:1276-1283. doi:10.1182/blood-2005-02-0819 (Pubitemid 43242359)
27. Pinilla-Ibarz J, McQuary A (2010) Chronic lymphocytic leukemia: putting new treatment options into perspective. Cancer Control 17:4-15; quiz 16
28. Polakis P (2012) Wnt signaling in cancer. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a008052
29. Pontiki E, Hadjipavlou-Litina D (2012) Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives. Med Res Rev 32:1-165. doi:10.1002/med.20200
30. Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 16:1015-1027. doi:10.1038/sj.leu.2402531 (Pubitemid 34618840)
31. Shami PJ, Saavedra JE, Wang LY et al (2003) JS-K, a glutathione/ glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2:409-417
32. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30. doi:10.3322/caac.21166
33. Sikandar S, Dizon D, Shen X et al (2010) The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 1:596-605
34. Tang J, Yan H, Zhuang S (2013) Histone deacetylases as targets for treatment of multiple diseases. Clin Sci 124:651-662. doi:10.1042/CS20120504
35. Tsuji N, Kobayashi M, Nagashima K et al (1976) A new antifungal antibiotic, trichostatin. J Antibiot 29:1-6
36. Turgut B, Vural O, Pala FS et al (2007) 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 48:311-320. doi:10.1080/ 10428190601059829 (Pubitemid 46994881)
37. Vigushin DM, Ali S, Pace PE et al (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7:971-976 (Pubitemid 32708736)
38. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179
39. Yoshida M, Horinouchi S, Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 17:423-430. doi:10.1002/bies.950170510
40. Zenz T, Mertens D, Döhner H, Stilgenbauer S (2011) Importance of genetics in chronic lymphocytic leukemia. Blood Rev 25:131-137. doi:10.1016/j.blre.2011.02.002
41. Zenz T, Gribben JG, Hallek M et al (2012) Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119:4101-4107. doi:10.1182/blood- 2011-11-312421
42. Zhang C, Richon V, Ni X et al (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052. doi:10.1111/j.0022-202X.2005.23925.x
43. Zhang Q, Major MB, Takanashi S et al (2007) Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci USA 104:7444-7448. doi:10.1073/pnas.0702136104 (Pubitemid 47185925)
44. Zhao L, Au JL-S, Wientjes MG (2010) Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) 2:241-249